Compare BioNTech SE - ADR (BNTX) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Southern Copper Corp — how do they compare? BioNTech SE - ADR trades at $90.07 (market cap $22.86B), while Southern Copper Corp trades at $179 (market cap $152.16B). The key difference: Southern Copper Corp is far larger — about 6.7× BioNTech SE - ADR's market cap, and Southern Copper Corp pays a 2.17% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | SCCO | |
|---|---|---|
Market Cap | $22.86B | $152.16B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $218.85 |
52-Week Low | $83.89 | $90.54 |
Enterprise Value | $6.53B | $154.22B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Southern Copper (SCCO) trades at $174.53, down 0.74% on the day, with a bearish technical signal and mixed analyst sentiment. The stock shows strong fundamentals, including a 32.3% net income margin and consistent earnings beats, with Q1 2026 EPS of $1.90 exceeding the $1.82 estimate. Revenue grew to $13.42 billion in 2025, and cash flow from operations reached $4.75 billion. Recent corporate actions include a $1.00 dividend and a 1:1.01 stock split effective May 13, 2026.
The outlook for SCCO is supported by robust profitability and growth in the copper sector, driven by AI and infrastructure demand, but risks include high valuation multiples and bearish technical indicators. Analyst consensus is cautious with a $151.58 price target below the current price, indicating potential downside despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
